Astellas Pharma Stock Equity Positions Weight
| YPH Stock | EUR 9.79 0.23 2.41% |
Astellas Pharma fundamentals help investors to digest information that contributes to Astellas Pharma's financial success or failures. It also enables traders to predict the movement of Astellas Stock. The fundamental analysis module provides a way to measure Astellas Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Astellas Pharma stock.
Astellas |
Astellas Pharma Company Equity Positions Weight Analysis
Astellas Pharma's Percentage of fund asset invested in equity instruments. About 80% of global funds and ETFs carry equity instruments on their balance sheet.
More About Equity Positions Weight | All Equity Analysis
Stock Percentage | = | % of Equities | in the fund |
Funds with most asset allocated to stocks can be subclassified into many different categories such as market capitalization or investment style.
| Competition |
According to the company disclosure, Astellas Pharma has an Equity Positions Weight of 0.0%. This indicator is about the same for the Healthcare average (which is currently at 0.0) sector and about the same as Drug Manufacturers—General (which currently averages 0.0) industry. This indicator is about the same for all Germany stocks average (which is currently at 0.0).
Did you try this?
Run Funds Screener Now
Funds ScreenerFind actively-traded funds from around the world traded on over 30 global exchanges |
| All Next | Launch Module |
Astellas Fundamentals
| Return On Equity | 0.0898 | |||
| Return On Asset | 0.0653 | |||
| Profit Margin | 0.09 % | |||
| Operating Margin | 0.17 % | |||
| Current Valuation | 24.85 B | |||
| Shares Outstanding | 1.83 B | |||
| Shares Owned By Insiders | 0.37 % | |||
| Shares Owned By Institutions | 50.33 % | |||
| Price To Earning | 29.54 X | |||
| Price To Book | 2.44 X | |||
| Price To Sales | 0.02 X | |||
| Revenue | 1.3 T | |||
| Gross Profit | 1.04 T | |||
| EBITDA | 241.52 B | |||
| Net Income | 124.09 B | |||
| Cash And Equivalents | 305.99 B | |||
| Cash Per Share | 165.15 X | |||
| Total Debt | 308 M | |||
| Current Ratio | 1.49 X | |||
| Book Value Per Share | 847.56 X | |||
| Cash Flow From Operations | 257.44 B | |||
| Earnings Per Share | 0.52 X | |||
| Number Of Employees | 14.52 K | |||
| Beta | 0.51 | |||
| Market Capitalization | 23.71 B | |||
| Total Asset | 2.33 T | |||
| Z Score | 45.6 | |||
| Annual Yield | 0.03 % | |||
| Five Year Return | 2.35 % | |||
| Net Asset | 2.33 T | |||
| Last Dividend Paid | 55.0 |
About Astellas Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Astellas Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Astellas Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Astellas Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Astellas Stock
Astellas Pharma financial ratios help investors to determine whether Astellas Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Astellas with respect to the benefits of owning Astellas Pharma security.